title: CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes.
abstract: We characterized the role of adenosine receptor (AR) subtypes in the modulation of glutamatergic neurotransmission by the chemokine fractalkine (CX3CL1) in mouse hippocampal CA1 neurons. CX(3)CL1 causes a reversible depression of excitatory postsynaptic current (EPSC), which is abolished by the A(3)R antagonist MRS1523, but not by A(1)R (DPCPX) or A(2A)R (SCH58261) antagonists. Consistently, CX3CL1-induced EPSC depression is absent in slices from A(3)R(-/-) but not A(1)R(-/-) or A(2A)R(-/-) mice. Further, A(3)R stimulation causes similar EPSC depression. In cultured neurons, CX3CL1-induced depression of AMPA current shows A(1)R-A(3)R pharmacology. We conclude that glutamatergic depression induced by released adenosine requires the stimulation of different ARs.
authors.affiliation: Istituto Pasteur-Fondazione Cenci Bolognetti & Dipartimento di Fisiologia e Farmacologia Sapienza Università di Roma, Piazzale A. Moro 5, 00185 Rome, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Piccinin
authors.forename: S
authors.initials: S
authors.lastname: Di Angelantonio
authors.forename: A
authors.initials: A
authors.lastname: Piccioni
authors.forename: R
authors.initials: R
authors.lastname: Volpini
authors.forename: G
authors.initials: G
authors.lastname: Cristalli
authors.forename: B B
authors.initials: BB
authors.lastname: Fredholm
authors.forename: C
authors.initials: C
authors.lastname: Limatola
authors.forename: F
authors.initials: F
authors.lastname: Eusebi
authors.forename: D
authors.initials: D
authors.lastname: Ragozzino
mesh_terms: D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D058918:Adenosine A3 Receptor Antagonists; D000818:Animals; D056547:CA1 Region, Hippocampal / Q000276:immunology* / Q000378:metabolism* / Q000648:ultrastructure; D002478:Cells, Cultured; D054428:Chemokine CX3CL1 / Q000502:physiology*; D019706:Excitatory Postsynaptic Potentials / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009433:Neural Inhibition / Q000235:genetics / Q000276:immunology*; D009924:Organ Culture Techniques; D018408:Patch-Clamp Techniques; D017729:Presynaptic Terminals / Q000276:immunology / Q000378:metabolism; D043682:Receptor, Adenosine A1 / Q000172:deficiency / Q000502:physiology; D043684:Receptor, Adenosine A3 / Q000172:deficiency / Q000502:physiology; D043683:Receptors, Adenosine A2 / Q000172:deficiency / Q000502:physiology; D018047:Receptors, Purinergic P1 / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D009435:Synaptic Transmission / Q000235:genetics / Q000276:immunology*
chemical_list: D058916:Adenosine A1 Receptor Antagonists; D058917:Adenosine A2 Receptor Antagonists; D058918:Adenosine A3 Receptor Antagonists; D054428:Chemokine CX3CL1; C515539:Cx3cl1 protein, mouse; D043682:Receptor, Adenosine A1; D043684:Receptor, Adenosine A3; D043683:Receptors, Adenosine A2; D018047:Receptors, Purinergic P1